Life sciences company Neogen (NASDAQ: NEOG) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 4.8% year on year to $225.5 million. The company’s full-year revenue guidance of $830 million at the midpoint came in 3.1% above analysts’ estimates. Its non-GAAP profit of $0.05 per share was 44.4% below analysts’ consensus estimates.

Is now the time to buy NEOG? Find out in our full research report (it’s free).

StockStory’s Take

Neogen’s second quarter saw a negative market reaction following results that reflected ongoing challenges in the company’s primary end markets. Management highlighted continued pressure on food producers due to prolonged inflation, leading to lower production volumes and a subdued environment for the Food Safety segment. CEO John Adent described the quarter as impacted by both external market softness and internal execution hurdles, particularly noting inefficiencies in sample collection production and elevated inventory write-offs. The segment’s pathogen detection and biosecurity products performed well, but these gains were offset by broader volume declines and operational costs.

Looking ahead, Neogen’s forward guidance is shaped by a cautious outlook for end market demand, but also by optimism around regulatory momentum and operational improvements. Management pointed to enhanced U.S. food safety policies, ongoing investments in pathogen testing, and a planned reduction in capital expenditures as factors supporting future growth. CFO Dave Naemura emphasized that while market conditions are expected to remain subdued, improvements in inventory management, tariff mitigation efforts, and successful execution of the Petrifilm production transition could gradually boost margins. The upcoming CEO transition is also expected to bring renewed focus on operational fundamentals.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to persistent market headwinds, production challenges, and a mixed regulatory landscape, while highlighting important portfolio moves and new product launches.

• Food Safety segment resilience: Despite weak end markets, Neogen’s pathogen detection and biosecurity product categories saw growth, supported by increased regulatory focus on food safety, especially with the USDA’s emphasis on Listeria testing.
• Sample collection inefficiencies: The integration of the 3M business led to significant manual production and operational inefficiencies in sample collection, resulting in higher costs and inventory write-offs. Management expects these issues to gradually improve but sees them as a near-term margin drag.
• Regulatory environment tailwinds: The USDA and FDA remain committed to food safety, with recent policy plans prioritizing enhanced microbiological testing. Neogen’s Molecular Detection System (MDS) is positioned as a primary method for Listeria detection, potentially supporting future demand.
• Portfolio simplification: The company completed the divestiture of its cleaners and disinfectants business and is progressing with the potential sale of its genomics business. These actions are aimed at streamlining operations and focusing on core areas.
• Petrifilm facility transition: The ramp-up of in-house Petrifilm production is a major operational milestone. Management expects improved gross margins once the transition is complete, though initial inefficiencies are expected as the facility comes online and SKUs are certified.

Drivers of Future Performance

Neogen’s outlook is shaped by cautious end market expectations, operational execution on key initiatives, and continued regulatory support for food safety.

• Operational improvements and cost control: Management’s improvement plan aims to address inefficiencies in sample collection, inventory management, and production processes. Success in these areas is expected to ease margin pressures and support gradual EBITDA recovery.
• Regulatory-driven growth opportunities: Enhanced food safety regulations, especially around pathogen testing for Listeria and Salmonella, are expected to drive demand for Neogen’s testing solutions. The company’s alignment with new USDA and FDA priorities could support above-market growth if effectively executed.
• Portfolio focus and capital discipline: The divestiture of non-core businesses and reduced capital expenditures are expected to simplify operations and accelerate deleveraging. These moves are designed to free up resources for investment in higher-margin core products and mitigate exposure to volatile segments.

Catalysts in Upcoming Quarters

Looking forward, our analyst team will monitor (1) the pace and efficiency of the Petrifilm facility transition and its impact on margins, (2) progress in resolving production inefficiencies and inventory management, and (3) the company’s ability to leverage regulatory changes and new product introductions in pathogen detection to drive revenue growth. Updates on the genomics business divestiture and CEO transition will also be key signposts.

Neogen currently trades at $5.16, down from $5.43 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.